This Article Full Text Full Text (PDF) All Versions of this Article: 90/2/151    most recent hh0202.104108v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rybalkin, S. D. Articles by Bornfeldt, K. E. Search for Related Content PubMed PubMed Citation Articles by Rybalkin, S. D. Articles by Bornfeldt, K. E. Related Collections Cell signalling/signal transduction Smooth muscle proliferation and differentiation

(Circulation Research. 2002;90:151.)
© 2002 American Heart Association, Inc.

Molecular Medicine

Cyclic Nucleotide Phosphodiesterase 1C Promotes Human Arterial Smooth Muscle Cell Proliferation

Sergei D. Rybalkin, Irina Rybalkina, Joseph A. Beavo, Karin E. Bornfeldt

From the Departments of Pharmacology (S.D.R., I.R., J.A.B.) and Pathology (K.E.B.), University of Washington School of Medicine, Seattle, Wash.

Correspondence to Karin E. Bornfeldt, Dept of Pathology, Box 357470, University of Washington School of Medicine, Seattle, WA 98195-7470. E-mail bornf{at}u.washington.edu

Proliferation of arterial smooth muscle cells (SMCs) is a key event in the formation of advanced atherosclerotic lesions and restenosis after angioplasty. Cyclic nucleotides (cAMP and cGMP) inhibit arterial SMC proliferation, and elevation of cyclic nucleotides reduces neointimal formation after angioplasty in animal models. Degradation of cAMP and cGMP is catalyzed by cyclic nucleotide phosphodiesterases (PDEs). One of these, PDE1C, hydrolyzes cAMP and cGMP and is expressed in proliferating human SMCs but is absent in quiescent human aorta. Thus, PDE1C expression is low in cultured human SMCs made quiescent by attaching to fibrillar collagen type I. After release from the fibrillar collagen, PDE1C expression is induced and associated with traverse through S-phase of the cell cycle. Further, PDE1C is expressed in vivo in human fetal aorta containing proliferating SMCs, but not in newborn aorta in which SMC proliferation has ceased. Inhibition of PDE1C in SMCs isolated from normal aorta or from lesions of atherosclerosis using antisense oligonucleotides or a PDE1 inhibitor results in suppression of SMC proliferation. In conclusion, PDE1C expression is a marker of human SMC proliferation ex vivo and in vivo. Inhibition of PDE1C leads to inhibition of human SMC proliferation. Because PDE1C is absent in quiescent SMCs, PDE1C inhibitors may target proliferating SMCs in lesions of atherosclerosis or restenosis.

Key Words: cAMP • cGMP • collagen • phosphodiesterase inhibitor

This article has been cited by other articles:

				M. C. Ortiz-Capisano, T.-D. Liao, P. A. Ortiz, and W. H. Beierwaltes Calcium-dependent phosphodiesterase 1C inhibits renin release from isolated juxtaglomerular cells Am J Physiol Regulatory Integrative Comp Physiol, November 1, 2009; 297(5): R1469 - R1476. [Abstract] [Full Text] [PDF]

				R. T. Schermuly, S. S. Pullamsetti, G. Kwapiszewska, R. Dumitrascu, X. Tian, N. Weissmann, H. A. Ghofrani, C. Kaulen, T. Dunkern, C. Schudt, et al. Phosphodiesterase 1 Upregulation in Pulmonary Arterial Hypertension: Target for Reverse-Remodeling Therapy Circulation, May 1, 2007; 115(17): 2331 - 2339. [Abstract] [Full Text] [PDF]

				M. D. Houslay, G. S. Baillie, and D. H. Maurice cAMP-Specific Phosphodiesterase-4 Enzymes in the Cardiovascular System: A Molecular Toolbox for Generating Compartmentalized cAMP Signaling Circ. Res., April 13, 2007; 100(7): 950 - 966. [Abstract] [Full Text] [PDF]

				C. Yan, C. L. Miller, and J.-i. Abe Regulation of Phosphodiesterase 3 and Inducible cAMP Early Repressor in the Heart Circ. Res., March 2, 2007; 100(4): 489 - 501. [Abstract] [Full Text] [PDF]

				F. Murray, H. H. Patel, R. Y. S. Suda, S. Zhang, P. A. Thistlethwaite, J. X.-J. Yuan, and P. A. Insel Expression and activity of cAMP phosphodiesterase isoforms in pulmonary artery smooth muscle cells from patients with pulmonary hypertension: role for PDE1 Am J Physiol Lung Cell Mol Physiol, January 1, 2007; 292(1): L294 - L303. [Abstract] [Full Text] [PDF]

				K. E. Bornfeldt Nuclear Signaling in Smooth Muscle Cells: Cyclic Nucleotide Phosphodiesterase 1A Moves In Circ. Res., March 31, 2006; 98(6): 720 - 722. [Full Text] [PDF]

				D. J. Nagel, T. Aizawa, K.-I. Jeon, W. Liu, A. Mohan, H. Wei, J. M. Miano, V. A. Florio, P. Gao, V. A. Korshunov, et al. Role of Nuclear Ca2+/Calmodulin-Stimulated Phosphodiesterase 1A in Vascular Smooth Muscle Cell Growth and Survival Circ. Res., March 31, 2006; 98(6): 777 - 784. [Abstract] [Full Text] [PDF]

				M. A. Giembycz Phosphodiesterase-4: Selective and Dual-Specificity Inhibitors for the Therapy of Chronic Obstructive Pulmonary Disease Proceedings of the ATS, November 1, 2005; 2(4): 326 - 333. [Abstract] [Full Text] [PDF]

				D. G. Tilley and D. H. Maurice Vascular Smooth Muscle Cell Phenotype-Dependent Phosphodiesterase 4D Short Form Expression: Role of Differential Histone Acetylation on cAMP-Regulated Function Mol. Pharmacol., September 1, 2005; 68(3): 596 - 605. [Abstract] [Full Text] [PDF]

				M. D. Houslay The Long and Short of Vascular Smooth Muscle Phosphodiesterase-4 As a Putative Therapeutic Target Mol. Pharmacol., September 1, 2005; 68(3): 563 - 567. [Abstract] [Full Text] [PDF]

				J. Wharton, J. W. Strange, G. M. O. Moller, E. J. Growcott, X. Ren, A. P. Franklyn, S. C. Phillips, and M. R. Wilkins Antiproliferative Effects of Phosphodiesterase Type 5 Inhibition in Human Pulmonary Artery Cells Am. J. Respir. Crit. Care Med., July 1, 2005; 172(1): 105 - 113. [Abstract] [Full Text] [PDF]

				T. A. Goraya, N. Masada, A. Ciruela, and D. M. F. Cooper Sustained Entry of Ca2+ Is Required to Activate Ca2+-Calmodulin-dependent Phosphodiesterase 1A J. Biol. Chem., September 24, 2004; 279(39): 40494 - 40504. [Abstract] [Full Text] [PDF]

				T. Munzel, R. Feil, A. Mulsch, S. M. Lohmann, F. Hofmann, and U. Walter Physiology and Pathophysiology of Vascular Signaling Controlled by Cyclic Guanosine 3',5'-Cyclic Monophosphate-Dependent Protein Kinase Circulation, November 4, 2003; 108(18): 2172 - 2183. [Full Text] [PDF]

				D. H. Maurice, D. Palmer, D. G. Tilley, H. A. Dunkerley, S. J. Netherton, D. R. Raymond, H. S. Elbatarny, and S. L. Jimmo Cyclic Nucleotide Phosphodiesterase Activity, Expression, and Targeting in Cells of the Cardiovascular System Mol. Pharmacol., September 1, 2003; 64(3): 533 - 546. [Abstract] [Full Text] [PDF]

				S. D. Rybalkin, C. Yan, K. E. Bornfeldt, and J. A. Beavo Cyclic GMP Phosphodiesterases and Regulation of Smooth Muscle Function Circ. Res., August 22, 2003; 93(4): 280 - 291. [Abstract] [Full Text] [PDF]